Placebo News and Research

RSS

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2012

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.

15 Oct 2012

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

Genentech, Inc., a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ACTEMRA (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

13 Oct 2012

Lenalidomide worsens survival, adverse events in prostate cancer

A combination of lenalidomide plus docetaxel and prednisone treatment in patients with chemotherapy-naive prostate cancer leads to worse overall survival rates and increased toxicity compared with placebo, show study results.

12 Oct 2012

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Today Biogen Idec announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date.

12 Oct 2012

Two CUMC studies provide new insights into spinal muscular atrophy

A study by scientists from the Motor Neuron Center at Columbia University Medical Center (CUMC) suggests that spinal muscular atrophy (SMA), a genetic neuromuscular disease in infants and children, results primarily from motor circuit dysfunction, not motor neuron or muscle cell dysfunction, as is commonly thought.

12 Oct 2012

Results from Aldagen’s ALD-401 Phase II trial on ischemic stroke

Early results of a Phase II intra-arterial stem cell trial for ischemic stroke showed no adverse events associated with the first 10 patients, allowing investigators to expand the study to a targeted total of 100 patients.

12 Oct 2012

Clinical study to investigate Cytori's adipose-derived cell therapy in patients with heart failure

Timothy Henry, M.D. of the Minneapolis Heart Institute Foundation treated the first patient in the ATHENA study, injecting the patient's own stem cells into the heart to restore blood flow and help regenerate heart muscle. Henry, the Foundation's Director of Research is co-principal investigator of the ATHENA study sponsored by Cytori Therapeutics.

12 Oct 2012

Heart drug could ease rare muscle disorder

The anti-arrhythmic drug mexiletine may improve symptoms in patients with nondystrophic myotonias, shows a small randomized trial published in JAMA.

11 Oct 2012

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).

11 Oct 2012

Leading scientists select first drugs to be evaluated in Alzheimer's clinical study

Leading scientists have selected the first drugs to be evaluated in a worldwide clinical study to determine whether they can prevent Alzheimer's disease.

11 Oct 2012

Testosterone fosters social behavior in men

The hormone testosterone stands for typically male attributes - it fosters the forming of the sexual characteristics, increases libido and muscle building. Women also have this sex hormone, but to a much lesser extent.

11 Oct 2012

Zero out of TEN for fecal incontinence treatment

Transcutaneous electrical nerve stimulation is no more effective than placebo for the treatment of fecal incontinence, say French researchers.

10 Oct 2012

HVLA manipulation comes out top for low-back pain

Spinal high-velocity-low-amplitude manipulation for the treatment of nonspecific low-back pain has shown to be superior to a nonsteroidal anti-inflammatory drug, researchers report.

9 Oct 2012

Lilly announces detailed results from solanezumab Phase 3 trials on Alzheimer's

Eli Lilly and Company today announced its detailed results for the Phase 3, double-blind, placebo-controlled EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease.

9 Oct 2012

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme, a Sanofi company, announced today new data from Genzyme's clinical development programs for AUBAGIO (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

9 Oct 2012

New neuroprotective agent for stroke patients potentially found

Scientists have shown that a drug called NA-1 results in fewer brain lesions in patients who have undergone surgery to repair a brain aneurysm, compared to placebo, and appears to be safe to use, according to an Article published Online First in The Lancet Neurology.

8 Oct 2012

Trevena reports completion of TRV027 Phase 2a study in advanced heart failure patients

Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it has successfully completed a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart failure with reduced ejection fraction.

8 Oct 2012

Positive results from Cempra's IV solithromycin Phase 1 study

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of its Phase 1 study of intravenous (IV) solithromycin in healthy subjects. The study demonstrated that IV solithromycin was well tolerated, showed a favorable pharmacokinetic profile (PK) and achieved relevant plasma concentrations.

8 Oct 2012

Data from GTx's enobosarm Phase IIb study on cancer to be presented at SIOG meeting

GTx, Inc. announced today there will be two scientific poster presentations on the effects of enobosarm, a selective androgen receptor modulator (SARM), on improving physical function and quality of life in middle aged and elderly cancer patients.

8 Oct 2012

Placebo News and Research

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

Lenalidomide worsens survival, adverse events in prostate cancer

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Two CUMC studies provide new insights into spinal muscular atrophy

Results from Aldagen’s ALD-401 Phase II trial on ischemic stroke

Clinical study to investigate Cytori's adipose-derived cell therapy in patients with heart failure

Heart drug could ease rare muscle disorder

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Leading scientists select first drugs to be evaluated in Alzheimer's clinical study

Testosterone fosters social behavior in men

Zero out of TEN for fecal incontinence treatment

HVLA manipulation comes out top for low-back pain

Lilly announces detailed results from solanezumab Phase 3 trials on Alzheimer's

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

New neuroprotective agent for stroke patients potentially found

Trevena reports completion of TRV027 Phase 2a study in advanced heart failure patients

Positive results from Cempra's IV solithromycin Phase 1 study

Data from GTx's enobosarm Phase IIb study on cancer to be presented at SIOG meeting

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News